Gyre Therapeutics (GYRE) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.04
- Estimate
- -$0.12
- Surprise
- +65.7%
- Score today
- 5.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Gyre Therapeutics (GYRE) reported a narrower loss than forecast — adjusted EPS of -$0.04 against the -$0.12 estimate (a 65.7% beat on a still-unprofitable quarter).
Coverage in the report window
- Gyre Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates — fiscal.ai, 2026-11-05
- Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $109.500M Est — benzinga, 2026-11-05
- Gyre Therapeutics Q3 EPS $(0.04) Beats $(0.13) Estimate, Sales $32.934M Beat $28.400M Estimate — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates GYRE Sell at 5.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +65.7% surprise compares with a +71.4% four-quarter average. Next scheduled report: 2027-03-11.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3)
- Consecutive earnings misses (2)
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.76
- Price target
- $6.96
- Stop
- $4.43
- Upside to target
- +46.2%
Risk check: trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
GYRE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $504.7M
- P/E (fwd)
- 79.3
- 52-week range
- $3.97–$9.14
- Off 52-week high
- 47.9%
- RSI (14)
- 39
- Volume vs avg
- 1.93×
- Score today
- 5.6/10